Mieloma múltiple en Chile: Respuesta a tratamiento en pacientes con mieloma múltiple elegibles para trasplante autólogo de progenitores hematopoyéticos.

Por lo tanto, en base a su perfil de eficacia y seguridad, ofatumumab debe considerarse una alternativa de tratamiento para pacientes con EMRR o EMSP con enfermedad activa

In concordance with these expectations and also in line with previous data from other groups [19–21], we were able to observe that dasatinib treatment effectively promoted

1) Spanish Society of Blood Transfusion and Cell Therapy. Guía sobre la transfusión de componentes sanguíneos y derivados plasmáticos. [Leucodepletion and autologous

Add-on therapy with saxagliptin in patients inadequately controlled on dapagliflozin plus metformin A 24-week randomised, double-blind, placebo-controlled study conducted on

El tratamiento de elección es la terapia combinada con quimioterapia a altas dosis, seguida de un trasplante autólogo de progenitores hematopoyéticos (TASPE). Sin

human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy. Stem Cell

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small- cell lung cancer after disease progression on platinum-based therapy

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone